Influenza H1N1 Vaccine

Name: Influenza H1N1 Vaccine

Dosage and Administration

Preparation for Administration

Inspect Influenza A (H1N1) 2009 Monovalent Vaccine syringes and multidose vials visually for particulate matter and/or discoloration prior to administration. If either of these conditions exists, the vaccine should not be administered.

Shake the syringe vigorously before administering the vaccine and shake the multidose vial preparation each time before withdrawing a dose of vaccine.

Between uses, return the multidose vial to the recommended storage conditions between 2º and 8ºC (36º and 46ºF). Do not freeze. Discard if the vaccine has been frozen.

A separate syringe and needle or a sterile disposable unit should be used for each injection to prevent transmission of infectious agents from one person to another. Needles should be disposed of properly and not recapped.

It is recommended that small syringes (0.5-mL or 1-mL) should be used to minimize any product loss.

Recommended Dose and Schedule

Clinical studies are ongoing with Influenza A (H1N1) 2009 Monovalent Vaccine to determine the optimal dosage, number of doses and schedule.

Available data show that children 9 years of age and younger are largely serologically naïve to the pandemic (H1N1) 2009 virus (15.1). Based upon these data Influenza A (H1N1) 2009 Monovalent Vaccine should be administered as follows:

Children (4 to 17 years of age):

Children 4 through 9 years of age should receive two 0.5mL doses by intramuscular injection approximately 1 month apart.

Children 10 through 17 years of age should receive a single 0.5-mL intramuscular injection.

The needle size may range from 7/8 to 1¼ inches, depending on the size of the child’s deltoid muscle, and should be of sufficient length to penetrate the muscle tissue. The anterolateral thigh can be used, but the needle should be longer, usually 1 inch.

The vaccine should not be injected in the gluteal region or areas where there may be a major nerve trunk.

Adults (18 years of age and older):

Influenza A (H1N1) 2009 Monovalent Vaccine should be administered as a single 0.5-mL intramuscular injection preferably in the region of the deltoid muscle of the upper arm.

A needle of ≥1 inch is preferred because needles <1 inch might be of insufficient length to penetrate muscle tissue in certain adults.

The vaccine should not be injected in the gluteal region or areas where there may be a major nerve trunk.

Dosage Forms and Strengths

Influenza A (H1N1) 2009 Monovalent Vaccine is a sterile suspension for intramuscular injection. [see DESCRIPTION (11) for the complete list of ingredients]

Influenza A (H1N1) 2009 Monovalent Vaccine is available in two presentations:

1) Prefilled single dose syringe, 0.5-mL. Thimerosal, a mercury derivative used during manufacture, is removed by subsequent purification steps to a trace amount (≤ 1 mcg mercury per 0.5-mL dose).

2) Multidose vial, 5-mL. Contains thimerosal, a mercury derivative, added as a preservative. Each 0.5-mL dose from the multidose vial contains 25 mcg mercury.

Drug Interactions

Concomitant Administration with Other Vaccines

There are no data to assess the concomitant administration of Influenza A (H1N1) 2009 Monovalent Vaccine with other vaccines. If Influenza A (H1N1) 2009 Monovalent Vaccine is to be given at the same time as another injectable vaccine(s), the vaccines should always be administered at different injection sites.

Influenza A (H1N1) 2009 Monovalent Vaccine should not be mixed with any other vaccine in the same syringe or vial.

Concurrent Use with Immunosuppressive Therapies

Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune response to Influenza A (H1N1) 2009 Monovalent Vaccine.

Influenza H1N1 Vaccine - Clinical Pharmacology

Mechanism of Action

Influenza illness and its complications follow infection with influenza viruses. Global surveillance of influenza identifies yearly antigenic variants. For example, since 1977, antigenic variants of influenza A (H1N1 and H3N2) viruses and influenza B viruses have been in global circulation. Specific levels of hemagglutination inhibition (HI) antibody titers post-vaccination with inactivated influenza virus vaccine have not been correlated with protection from influenza illness. In some human studies, antibody titer of ≥1:40 have been associated with protection from influenza illness in up to 50% of subjects [see REFERENCES (15.2, 15.3)].

Antibody against one influenza virus type or subtype confers limited or no protection against another. Furthermore, antibody to one antigenic variant of influenza virus might not protect against a new antigenic variant of the same type or subtype.

Clinical Studies

Novartis’ Influenza A (H1N1) 2009 Monovalent Vaccine and seasonal trivalent Influenza Virus Vaccine (FLUVIRIN) are manufactured by the same process. Data in this section were obtained in clinical studies conducted with FLUVIRIN.

Between 1982 and 1991, twelve clinical studies were conducted in healthy adult and geriatric subjects and one in children between 4 and 12 years of age who were considered to be ‘at risk’. Since 1991 an annual clinical study has been conducted in the UK in healthy adults aged 18 years or older. FLUVIRIN was also used as a control in a US clinical trial in adults (18-49 years of age). In all the trials, blood samples were taken prior to vaccination and approximately three weeks after vaccination to assess the immunogenic response to vaccination by measurement of anti-HA antibodies.

Three clinical studies were carried out between 1995 and 2004 in a total of 520 pediatric subjects (age range 6-48 months). Of these, 285 healthy subjects plus 41 ‘at risk’ pediatric subjects, received FLUVIRIN.

Influenza A (H1N1) 2009 Monovalent Vaccine should only be used for the immunization of persons aged 4 years and over.

Immunogenicity in Adults (18 to 64 years of age)

Tables 4 and 5 show the immunogenicity data for the adult age group. The seven clinical studies presented enrolled a total of 774 adult subjects. In the adult group, for all antigens (A/H1N1, A/H3N2 and B) at least one of the following point estimate criteria was met: the proportion of subjects with seroconversion (post-vaccination titer ≥1:40 from a pre-vaccination titer <1:10) or significant increase (at least a four-fold increase from pre-vaccination titer ≥1:10) in antibody titer was greater than 40%; the geometric mean titer (GMT) increase was >2.5; the proportion of subjects with a post-vaccination hemagglutination inhibition (HI) antibody titer ≥1:40 was greater than 70%.

TABLE 4 Summary of the Seroconversion and Proportion of Subjects Achieving an HI titer ≥1:40 for Adult Subjects
Year/Strain No. of subjects Seroconversion ∞ HI titer ≥1:40¥
N % 95% CIΦ N % 95% CIΦ

∞ Seroconversion: proportion of subjects with either a post-vaccination HI titer ≥1:40 from a pre-vaccination titer <1:10 or at least a four-fold increase from pre-vaccination HI titer ≥1:10 in antibody titer.

¥ HI titer ≥1:40: proportion of subjects with a post-vaccination titer ≥ 1:40.

Φ 95% CI: 95% confidence interval

1998-1999
    A/H1N1 48 73 (62, 83) 50 76 (65, 86)
    A/H3N2 66 43 65 (54, 77) 47 71 (60, 82)
    B 42 64 (52, 75) 62 94 (88, 100)
1999-2000
    A/H1N1 45 59 (48, 70) 50 66 (55, 76)
    A/H3N2 76 51 67 (57, 78) 66 87 (79, 94)
    B 53 70 (59, 80) 75 99 (96, 100)
2000-2001
    A/H1N1 41 55 (44, 67) 41 55 (44, 67)
    A/H3N2 74 45 61 (50, 72) 52 84 (75, 92)
    B 50 68 (57, 78) 73 99 (96, 100)
2001-2002
    A/H1N1 44 59 (48, 70) 48 64 (53, 75)
    A/H3N2 75 46 61 (50, 72) 68 91 (84, 97)
    B 42 56 (45, 67) 66 88 (81, 95)
2002-2003
    A/H1N1 62 58 (49, 68) 73 69 (60, 78)
    A/H3N2 106 72 68 (59, 77) 93 88 (81, 94)
    B 78 74 (65, 82) 101 95 (91, 99)
2004-2005
    A/H1N1 52 70 (59, 80) 66 89 (80, 95)
    A/H3N2 74 60 81 (70, 89) 73 99 (93, 100)
    B 57 77 (66, 86) 69 93 (85, 98)
2005-2006
    A/H1N1 191 63 (57, 68) 296 98 (95, 99)
    A/H3N2 303 273 90 (86, 93) 294 97 (94, 99)
    B 213 70 (65, 75) 263 87 (82, 90)
TABLE 5 Summary of the Geometric Mean Hemagglutination Inhibition Antibody Titers, Pre- and Post-Immunization, for Adult Subjects
Year/Strain No. of subjects Geometric Mean Titer (GMT)
Pre-vaccination Post-vaccination Fold Increase (95% CI)*

* 95% CI: 95% confidence interval

1998-1999
    A/H1N1 7.26 160.87 22.16 (14.25, 34.46)
    A/H3N2 66 8.23 87.02 10.57 (6.91, 16.16)
    B 20.97 231.07 110.2 (6.90, 17.59)
1999-2000
    A/H1N1 7.43 58.95 7.93 (5.73, 10.97)
    A/H3N2 76 15.29 122.83 8.03 (5.80, 11.13)
    B 25.70 254.76 9.91 (6.97, 14.10)
2000-2001
    A/H1N1 5.42 33.80 6.24 (4.49, 8.69)
    A/H3N2 74 15.98 126.01 7.89 (5.61, 11.09)
    B 26.24 308.25 11.75 (7.73, 17.85)
2001-2002
    A/H1N1 7.76 54.78 7.06 (5.24, 9.52)
    A/H3N2 75 23.67 153.81 6.50 (4.78, 8.84)
    B 19.91 107.53 5.40 (3.95, 7.38)
2002-2003
    A/H1N1 7.78 60.39 7.77 (5.81, 10.39)
    A/H3N2 106 23.32 292.03 12.52 (8.77, 17.87)
    B 30.20 314.11 10.40 (7.54, 14.34)
2004-2005
    A/H1N1 13 159 12 (8.39, 17)
    A/H3N2 74 37 658 18 (12, 26)
    B 15 156 11 (7.87, 14)
2005-2006
    A/H1N1 29 232 8 (6.68, 9.59)
    A/H3N2 303 14 221 15 (14, 17)
    B 13 83 6.5 (5.73, 7.37)

Immunogenicity in Geriatric Subjects (65 years of age and older)

Tables 6 and 7 show the immunogenicity of FLUVIRIN in the geriatric age group. The six clinical studies presented enrolled a total of 296 geriatric subjects. For each of the influenza antigens, the percentage of subjects who achieved seroconversion and the percentage of subjects who achieved HI titers of ≥1:40 are shown, as well as the fold increase in GMT.

For all antigens (A/H1N1, A/H3N2 and B) at least one of the following point estimate criteria was met: the proportion of subjects with seroconversion (post-vaccination titer ≥1:40 from a pre-vaccination titer <1:10) or significant increase (at least a four-fold increase from pre-vaccination titer ≥1:10) in antibody titer was greater than 30%; the geometric mean titer (GMT) increase was >2.0; the proportion of subjects with a post-vaccination hemagglutination inhibition (HI) antibody titer ≥1:40 was greater than 60%. The pre-specified efficacy criteria were met in each study, although a relatively lower immunogenicity of A/H1N1 strain was seen in the last four studies (the same strain was in each of the formulations).

TABLE 6 Summary of the Seroconversion and Proportion of Subjects Achieving an HI titer ≥1:40 for Geriatric Subjects
Year/Strain No. of subjects Seroconversion ∞ HI titer ≥1:40¥
N % 95% CIΦ N % 95% CIΦ

∞ Seroconversion: proportion of subjects with either a post-vaccination HI titer ≥1:40 from a pre-vaccination titer <1:10 or at least a four-fold increase from pre-vaccination HI titer ≥1:10 in antibody titer

¥ HI titer ≥1:40: proportion of subjects with a post-vaccination titer ≥1:40

Φ 95% CI: 95% confidence interval

1998-1999
    A/H1N1 33 79 (66, 91) 38 90 (82, 99)
    A/H3N2 42 33 79 (66, 91) 36 86 (75, 96)
    B 13 31 (17, 45) 42 100 (100, 100)
1999-2000
    A/H1N1 10 29 (14, 45) 23 68 (52, 83)
    A/H3N2 34 18 53 (36, 70) 31 91 (82, 100)
    B 9 26 (12, 41) 32 94 (86, 100)
2000-2001
    A/H1N1 5 14 (3, 26) 10 29 (14, 44)
    A/H3N2 35 22 63 (47, 79) 31 89 (78, 99)
    B 13 37 (21, 53) 33 94 (87, 100)
2001-2002
    A/H1N1 5 14 (3, 26) 14 40 (24, 56)
    A/H3N2 35 15 43 (26, 59) 33 94 (87, 100)
    B 6 17 (5, 30) 32 91 (82, 100)
2002-2003
    A/H1N1 24 27 (18, 36) 52 58 (48, 69)
    A/H3N2 89 42 47 (37, 58) 85 96 (91, 100)
    B 41 46 (36, 56) 86 97 (93, 100)
2004-2005
    A/H1N1 17 28 (17, 41) 46 75 (63, 86)
    A/H3N2 61 29 48 (35, 61) 60 98 (91, 100)
    B 38 62 (49, 74) 51 84 (72, 92)
TABLE 7 Summary of the Geometric Mean Hemagglutination Inhibition Antibody Titers, Pre- and Post-Immunization, for Geriatric Subjects
Year/Strain No. of subjects Geometric Mean Titer (GMT)
Pre-vaccination Post-vaccination Fold Increase (95% CI)*

* 95% CI: 95% confidence interval

1998-1999
    A/H1N1 13.92 176.65 12.69 (8.24, 19.56)
    A/H3N2 42 10.69 124.92 11.69 (7.02, 19.46)
    B 114.1 273.56 2.40 (1.82, 3.17)
1999-2000
    A/H1N1 15.82 50.58 3.20 (2.13, 4.80)
    A/H3N2 34 28.00 133.19 4.76 (2.92, 7.76)
    B 57.16 127.86 2.24 (1.56, 3.20)
2000-2001
    A/H1N1 6.66 18.85 2.83 (1.91, 4.18)
    A/H3N2 35 25.87 140.68 5.44 (3.72, 7.96)
    B 61.24 191.23 3.12 (2.13, 4.59)
2001-2002
    A/H1N1 12.69 26.65 2.10 (1.55, 2.84)
    A/H3N2 35 47.33 114.26 2.41 (1.73, 3.38)
    B 45.49 91.89 2.02 (1.47, 2.78)
2002-2003
    A/H1N1 13.29 31.92 2.40 (1.90, 3.03)
    A/H3N2 89 65.86 272.79 4.14 (3.09, 5.55)
    B 74.87 288.57 3.85 (2.89, 5.13)
2004-2005
    A/H1N1 21 64 3.13 (2.33, 4.2)
    A/H3N2 61 72 320 4.43 (3.13, 6.27)
    B 20 114 5.69 (4.39, 7.38)

Immunogenicity in Pediatric Subjects

A small-scale study was conducted in 1987 to evaluate safety and immunogenicity of FLUVIRIN in 38 ‘at risk’ children, with diabetes and/or asthma, or lymphoid leukemia. Thirty-eight participants aged between 4 and 12 years of age were assessed. Ten subjects had diabetes, 21 had asthma, two had both diabetes and asthma, and one had lymphoid leukemia. There were four healthy control subjects. All participants received a single 0.5-mL dose of FLUVIRIN.

Immunogenicity results were obtained for 19 of the 38 subjects enrolled in the study. The point estimate of the percentage of subjects achieving a titer of ≥ 1:40 was 84% for the A/H1N1 strain 79% for the B strain, and 53% for the A/H3N2 strain. The GMT fold increases were 5.8 for the A/H1N1 strain, 40 for the B strain and 17.7 for the A/H3N2 strain.

Three clinical studies were carried out between 1995 and 2004 in a total of 520 pediatric subjects (age range 6-47 months). Of these, 285 healthy subjects plus 41 ‘at risk’ pediatric subjects, received FLUVIRIN.

In a 1995/1996 clinical study, 41 subjects (aged 6-36 months) at increased risk for influenza-related complications received two 0.25-mL doses of FLUVIRIN. At least 49% of subjects showed a ≥4-fold increase in HI antibody titer to all three strains. HI antibody titers of 1:40 or greater were seen in at least 71% of the subjects for all three influenza strains, with increases in geometric mean titer of 6.0-fold or greater to all three strains.

Two clinical studies (1999-2000 and 2004) indicated a lower immunogenicity profile for FLUVIRIN compared with two commercial split vaccines; in a study in the age group 6-48 months the comparator was a US licensed vaccine, Fluzone®, and in another study in the age group 6-36 months the comparator was a non-US licensed inactivated influenza vaccine. Despite the small sample size (a total of 285 healthy subjects received FLUVIRIN in these two clinical studies) the lower immunogenicity profile of FLUVIRIN was greatest versus the comparator vaccines in children <36months but was also evident in those 36-48 months of age, though the differences were less.

Influenza A (H1N1) 2009 Monovalent Vaccine should only be used for the immunization of persons aged 4 years and older.

References

15.1    CDC. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR 2009; 58(19): 521-4.

15.2    Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004; 103:133-138.

15.3    Hobson D, Curry RL, Beare A, et. al. The role of serum hemagglutinin-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg Camb 1972; 767-777.

(web3)